Nerve Sheath Neoplasms: Clinical Trials

154 trials for Nerve Sheath Neoplasms, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

66 completed, 23 recruiting, 23 terminated, 16 active not recruiting. 154 Phase 2, 32 Phase 1, 6 Phase 3.

By phase and status

PhaseTrialsStatus
Phase 2154Completed 66, Recruiting 23, Terminated 23, Active not recruiting 16, Not yet recruiting 10, Unknown 10, Withdrawn 5, Enrolling by invitation 1
Phase 132Recruiting 9, Completed 7, Active not recruiting 6, Terminated 5, Not yet recruiting 3, Enrolling by invitation 1, Unknown 1
Phase 36Terminated 4, Completed 1, Unknown 1

Follow Nerve Sheath Neoplasms: new trials by email Literature Review of Nerve Sheath Neoplasms trials Research Report on Nerve Sheath Neoplasms

Trials (filtered) newest first · largest first

All 154 trials

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
Efficacy of Mirdametinib Alone or Combination With Radiotherapy for Germline and Sporadic NF1-Altered High-Grade Glioma
mirdametinib with radiation, mirdametinib - Neurofibromatosis 1 (NF1)
Phase 2Not yet recruitingUniversity of Alabama at Birmingham552027-01-012026-10-05
Combination of Avutometinib and Defactinib for Treatment of Relapsed, Refractory, Metastatic, or Unresectable Malignant Peripheral Nerve Sheath Tumor
avutometinib capsule + defactinib tablet - MPNST (Malignant Peripheral Nerve Sheath Tumor)
Phase 2Not yet recruitingGirish Dhall, MD252027-01-012026-10-28
Selumetinib for NF2-Related Schwannomatosis
Selumetinib - Neurofibromatosis Type 2, NF2
Phase 2Not yet recruitingBeijing Tiantan Hospital202026-12-012026-10-28
Trial of Selumetinib and Bromodomain Inhibitor With Durvalumab for Sarcomas
Selumetinib + ZEN-3694 ± Durvalumab - MPNST, NF1
Phase 2RecruitingUniversity of Alabama at Birmingham412026-08-042026-08-24
Safety and Efficacy of BMS-986504 in Unresectable Malignant Peripheral Nerve Sheath Tumor
BMS-986504 - Malignant Peripheral Nerve Sheath Tumors, MPNST
Phase 1 / Phase 2RecruitingAnkit Mangla, MD172026-08-012026-08-11
Luvometinib in Combination With Serplulimab for NF2-Related Tumors
Luvometinib, Serplulimab - NF2-related Schwannomatosis, NF2
Phase 1 / Phase 2Not yet recruitingBeijing Tiantan Hospital302026-07-312026-07-16
Platform Research for Innovative Medicines in NF2-SWN (PRIME-NF2)
Selumetinib 25mg/m2, Luvometinib, Serplulimab - Neurofibromatosis Type 2, Vestibular Schwannoma
Phase 2Not yet recruitingBeijing Tiantan Hospital2002026-07-182026-07-20
Study to Determine Optimal Dose, Evaluate the Efficacy and Safety of PRG-N-01 in Patients With Neurofibromatosis Type II
Trineumin - Neurofibromatosis Type II, NF2
Phase 1 / Phase 2Not yet recruitingPRG Science & Technology Co., Ltd.252026-07-012026-01-23
Early Phase Study Evaluating MEK and MDM2 Inhibition in Patients With NF1 and MPNST
APG-115, Selumetinib - Malignant Peripheral Nerve Sheath Tumor (MPNST), Neurofibromatosis 1 (NF1)
Phase 1 / Phase 2RecruitingAeRang Kim452026-06-012026-07-27
Alpha/Beta T and B Cell Depletion With Zoledronic Acid for Solid Tumors
Miltenyi CliniMACS Prodigy ® system, Zoledronic acid - Neuroblastoma, Rhabdomyosarcoma
Phase 1 / Phase 2RecruitingUniversity of Florida272026-02-112026-06-30
Mirdametinib in Patients With Advanced NF1-mutant Melanoma
Mirdametinib - Advanced Unresectable Melanoma, Metastatic Melanoma
Phase 2RecruitingKevin Kim, MD102025-10-132025-11-19
Pain Outcomes After Digital Amputation Using Tulavi Allay™ Nerve Cap
Tulavi allay Nerve Cap - Neuroma, Neuropathic Pain
Phase 2RecruitingMassachusetts General Hospital202025-09-202026-04-17
Selumetinib for the Prevention of Plexiform Neurofibroma Growth in NF Type 1
Selumetinib - Neurofibromatosis 1, Plexiform Neurofibroma
Phase 2RecruitingUniversity of Alabama at Birmingham2002025-08-272026-05-29
Follow-up Study to Evaluate the Safety and Efficacy of FCN-159 in Pediatric Participants With Neurofibromatosis Type 1
Luvometinib Tablets - Neurofibromatosis 1, Plexiform Neurofibroma
Phase 1 / Phase 2Not yet recruitingShanghai Fosun Pharmaceutical Industrial Development Co. Ltd.652025-06-122025-06-17
Using CICS-1 and SPM-011 and [18F]FBPA Commissioned by CICS and Sumitomo Heavy Industries and STELLA PHARMA
BNCT, [18F]FBPA - Thoracic Solid Malignant Tumor
Phase 1 / Phase 2Enrolling by invitationStella Pharma Corporation302025-04-102025-11-19
IO Combined With AI as First-line Treatment for Patients With Soft Tissue Sarcoma(TAIS)
Tislelizumab+liposomal doxorubicin+ifosfamide - Soft Tissue Sarcomas, Angiosarcoma
Phase 2RecruitingFudan University452025-02-252026-01-08
A Phase 2, Open-Label Study to Evaluate the Safety and Effects of HLX-1502 in Patients With Neurofibromatosis Type 1
HLX-1502 - Neurofibromatosis Type 1
Phase 2RecruitingHealx Limited252025-02-102026-07-29
Anti-VEGF Gene Therapy Trial for Vestibular Schwannoma
AAVAnc80-antiVEGF via Akouos Delivery Device - Vestibular Schwannoma
Phase 1 / Phase 2RecruitingEli Lilly and Company272025-01-172026-11-04
Low-dose Selumetinib for the Treatment of Plexiform Neurofibromas in Chinese Children
Selumetinib - Plexiform Neurofibromas (PN)
Phase 2Not yet recruitingWest China Hospital502025-01-012025-01-08
A Phase I/II Study of Trametinib and Azacitidine for Patients With Newly Diagnosed Juvenile Myelomonocytic Leukemia
Trametinib, Azacitidine, Fludarabine - Leukemia, Juvenile Myelomonocytic, JMML
Phase 1 / Phase 2RecruitingTherapeutic Advances in Childhood Leukemia Consortium582024-10-112026-09-04

Showing 20 of 154. Sign in to see all of them.

Narrower conditions

Neurofibrosarcoma (57)  ·  Neurofibromatosis 1 (55)  ·  Sarcoma (40)  ·  Leiomyosarcoma (30)  ·  Sarcoma, Synovial (29)  ·  Neurofibroma, Plexiform (28)  ·  Histiocytoma, Malignant Fibrous (25)  ·  Liposarcoma (24)  ·  Neurofibromatosis 2 (24)  ·  Fibrosarcoma (23)  ·  Neuroma, Acoustic (22)  ·  Hemangiosarcoma (21)  ·  Rhabdomyosarcoma (19)  ·  Sarcoma, Alveolar Soft Part (17)  ·  Neurofibromatoses (15)

Broader conditions

Neoplasms by Histologic Type (154)  ·  Neoplasms, Nerve Tissue (153)  ·  Neoplasms (152)  ·  Nervous System Diseases (152)  ·  Neurofibroma (131)  ·  Neuromuscular Diseases (123)  ·  Peripheral Nervous System Diseases (121)  ·  Nervous System Neoplasms (120)  ·  Peripheral Nervous System Neoplasms (115)  ·  Congenital, Hereditary, and Neonatal Diseases and Abnormalities (90)  ·  Genetic Diseases, Inborn (88)  ·  Neoplastic Syndromes, Hereditary (88)  ·  Neurodegenerative Diseases (86)  ·  Heredodegenerative Disorders, Nervous System (85)

Interventions

AZD 6244 (17)  ·  Doxorubicin (8)  ·  Imatinib Mesylate (7)  ·  Everolimus (6)  ·  Bevacizumab (5)  ·  Sirolimus (5)  ·  pazopanib (5)  ·  trametinib (5)  ·  Ifosfamide (4)  ·  mirdametinib (4)  ·  Lovastatin (3)  ·  pembrolizumab (3)  ·  Acetylcysteine (2)  ·  Etoposide (2)  ·  Inhalation (2)

Sponsors

National Cancer Institute (NCI) (19)  ·  University of Alabama at Birmingham (10)  ·  European Organisation for Research and Treatment of Cancer - EORTC (7)  ·  Memorial Sloan Kettering Cancer Center (6)  ·  Massachusetts General Hospital (5)  ·  Sarcoma Alliance for Research through Collaboration (5)  ·  Beijing Tiantan Hospital (4)  ·  Novartis Pharmaceuticals (4)  ·  Children's Hospital Medical Center, Cincinnati (3)  ·  Indiana University (3)  ·  NYU Langone Health (3)  ·  Assistance Publique - Hôpitaux de Paris (2)  ·  AstraZeneca (2)  ·  Maria Sklodowska-Curie National Research Institute of Oncology (2)  ·  Massachusetts Eye and Ear Infirmary (2)

Countries

United States (105)  ·  China (13)  ·  France (8)  ·  Canada (7)  ·  Germany (7)  ·  Belgium (6)  ·  Netherlands (6)  ·  United Kingdom (6)  ·  Spain (5)  ·  Australia (4)  ·  Denmark (4)  ·  Austria (3)  ·  Poland (3)  ·  Brazil (2)  ·  Japan (2)

Top investigators

Brigitte C Widemann, M.D. (5)  ·  AeRang Kim, MD, PhD (3)  ·  Girish Dhall, MD (3)  ·  Matthias A Karajannis, MD, MS (3)  ·  Scott Plotkin, MD (3)  ·  Brigitte C. Widemann, MD (2)  ·  Brigitte Widemann, MD (2)  ·  Chie-Schin Shih, MD (2)  ·  D. Bradley Welling, MD, PhD (2)  ·  Fu Zhao (2)  ·  Pinan Liu (2)  ·  William Tap, MD (2)  ·  Zhiquan Huang, doctoral (2)  ·  Aaron R Weiss (1)

Results publications

PMID 28029918, PMID 32187457, PMID 15683544, PMID 17105749, PMID 21996156, PMID 22353803, PMID 26851632, PMID 28230061, PMID 28409229, PMID 31010905, PMID 31582003, PMID 33354735, PMID 33863389, PMID 34541874, PMID 11705489, PMID 12528778, PMID 12957454, PMID 15010069, PMID 15177491, PMID 15592836, PMID 15659504, PMID 16528479, PMID 17095209, PMID 17336054, PMID 19088049, PMID 19451429, PMID 19451433, PMID 20471824, PMID 23099009, PMID 23382028, PMID 24215845, PMID 24500418, PMID 24753394, PMID 26976425, PMID 27502708, PMID 27510726, PMID 27956565, PMID 29718344, PMID 30284154, PMID 30339775, PMID 30410720, PMID 31151904, PMID 31401903, PMID 31881853, PMID 31969335, PMID 32089640, PMID 32562630, PMID 32702309, PMID 32827353, PMID 33362722

NIH funding

U10CA180886 (4), P30CA008748 (3), N01CM62206 (2), U10CA098543 (2), U10CA180821 (2), 2009 (1), 2016 (1), 2017 (1), 2018 (1), N01CM17104 (1), N01CM62201 (1), N01CM62205 (1), P30CA006973 (1), P30CA012197 (1), P30CA013148 (1)